Synthesis and structure-activity relationships of novel, substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 954-958

  Lee, Ga Eun ^a   Lee, Ho Sung ^a   Lee, So Deok ^a   Kim, Jung Ho ^b   Kim, Won Ki ^c   Kim, Yong Chul ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Hanwha Corporation   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Antagonist; Ethidium uptake; Human P2X7 receptor; IL 1 release; Iminium quaternary protoberberine alkaloids

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; A 740003; BERBERINE DERIVATIVE; CHELERYTHRINE; ETHIDIUM; INTERLEUKIN 1BETA; MRS 2306; PALMATINE; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; STRUCTURE ACTIVITY RELATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ALKALOIDS; BERBERINE ALKALOIDS; CELL DIFFERENTIATION; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ETHIDIUM; HUMANS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MODELS, CHEMICAL; QUINOLIZINES; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58549113754     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.088     Document Type: Article

References (39)

1. Tsukimoto M., Harada H., and Degawa M. Drug Discovery Today: Therapeutic Strategies 4 (2007) 33
2. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., and Di Virgilio F. J. Immunol. 176 (2006) 3877
3. Gabel C.A. Purinergic Signal. 3 (2007) 27
4. Moller B., and Villiger P.M. Springer Semin. Immunopathol. 27 (2006) 391
5. McCulloch C.A., Downey G.P., and El-Gabalawy H. Nat. Rev. Drug Disc. 5 (2006) 864
6. North R.A., and Barnard E.A. Curr. Opin. Neurobiol. 7 (1997) 346
7. Ralevic V., and Burnstock G. Pharmacol. Rev. 50 (1998) 413
8. Illes P. Drug Dev. Res. 53 (2001) 140
9. Bianco F., Fumagalli M., Pravettoni E., D'Ambrosi N., Volonte C., Matteoli M., Abbracchio M.P., and Verderio C. Brain Res. Brain Res. Rev. 48 (2005) 144
10. Roberts J.A., Vial C., Digby H.R., Agboh K.C., Wen H., Atterbury-Thomas A., and Evans R.J. Pflugers Arch. 452 (2006) 486
11. Steinberg T.H., Newman A.S., Swanson J.A., and Silverstein S.C. J. Biol. Chem. 262 (1987) 8884
12. Di Virgilio F. Immunol. Today 16 (1995) 524
13. Surprenant A., Rassendren F., Kawashima E., North R.A., and Buell G. Science 272 (1996) 735
14. Adinolfi E., Pizzirani C., Idzko M., Panther E., Norgauer J., Di Virgilio F., and Ferrari D. Purinergic Signal. 1 (2005) 219
15. Brough D., Le Feuvre R.A., Iwakura Y., and Rothwell N.J. Mol. Cell. Neurosci. 19 (2002) 272
16. Inoue K., Tsuda M., and Tozaki-Saitoh H. Purinergic Signal. 3 (2007) 311
17. Baraldi P.G., Di Virgilio F., and Romagnoli R. Curr. Top. Med. Chem. 4 (2004) 1707
18. Gunosewoyo H., Coster M.J., and Kassiou M. Curr. Top. Med. Chem. 14 (2007) 1505
19. Gargett C.E., and Wiley J.S. Br. J. Pharmacol. 120 (1997) 1483
20. Humphreys B.D., Virginio C., Surprenant A., Rice J., and Dubyak G.R. Mol. Pharmacol. 54 (1998) 22
21. Chen W., Ravi R.G., Kertesy S.B., Dubyak G.R., and Jacobson K.A. Bioconjugate Chem. 13 (2002) 1100
22. Ravi R.G., Kertesy S.B., Dubyak G.R., and Jacobson K.A. Drug Dev. Res. 54 (2001) 75
23. Lee G.E., Joshi B.V., Chen W., Jeong L.S., Moon H.R., Jacobson K.A., and Kim Y.C. Bioorg. Med. Chem. Lett. 18 (2008) 571
24. Baraldi P.G., Romagnoli R., Tabrizi M.A., Falzoni S., and Di Virgilio F. Bioorg. Med. Chem. Lett. 10 (2000) 681
25. Baraldi P.G., del Carmen Nuñez M., Morelli A., Falzoni S., Di Virgilio F., and Romagnoli R. J. Med. Chem. 46 (2003) 1318
26. Romagnoli R., Baraldi P.G., Carrion M.D., Cara C.L., Preti D., Cruz-Lopez O., Tabrizi M.A., Moorman A.R., Gessi S., Fogli E., Sacchetto V., and Borea P.A. J. Med. Chem. 50 (2007) 3706
27. Baxter A., Bent J., Bowers K., Braddock M., Brough S., Fagura M., Lawson M., McInally T., Mortimore M., Robertson M., Weaver R., and Webborn P. Bioorg. Med. Chem. Lett. 13 (2003) 4047
28. Furber M., Alcaraz L., Bent J.E., Beyerbach A., Bowers K., Braddock M., Caffrey M.V., Cladingboel D., Collington J., Donald D.K., Fagura M., Ince F., Kinchin E.C., Laurent C., Lawson M., Luker T.J., Mortimore M.M.P., Pimm A.D., Riley R.J., Roberts N., Robertson M., Theaker J., Thorne P.V., Weaver R., Webborn P., and Willis P. J. Med. Chem. 50 (2007) 5882
29. Nelson D.W., Gregg R.J., Kort M.E., Perez-Medrano A., Voight E.A., Wang Y., Grayson G., Namovic M.T., Donnelly-Roberts D.L., Niforatos W., Honore P., Jarvis M.F., Faltynek C.R., and Carroll W.A. J. Med. Chem. 49 (2006) 3659
30. Carroll W.A., Kalvin D.M., Perez Medrano A., Florjancic A.S., Wang Y., Donnelly-Roberts D.L., Namovic M.T., Grayson G., Honoré P., and Jarvis M.F. Bioorg. Med. Chem. Lett. 17 (2007) 4044
31. Honore P., Donnelly-Roberts D., Namovic M.T., Hsieh G., Zhu C.Z., Mikusa J.P., Hernandez G., Zhong C., Gauvin D.M., Chandran P., Harris R., Medrano A.P., Carroll W., Marsh K., Sullivan J.P., Faltynek C.R., and Jarvis M.F. J. Pharmacol. Exp. Ther. 319 (2006) 1376
32. Shemon A.N., Sluyter R., Conigrave A.D., and Wiley J.S. Br. J. Pharmacol. 142 (2004) 1015
33. http://www.chembank.or.kr/.
34. Grycová L., Dostál J., and Marek R. Phytochemistry 68 (2007) 150
35. Kametani T., Sugai T., Shoji Y., Honda T., Satoh F., and Fukumoto K. J. Chem. Soc., Perkin Trans. 1 (1977) 1151
36. Saá C., Guitián E., Castedo L., Suau R., and Saá J.M. J. Org. Chem. 51 (1986) 2781
37. + was determined by measuring fluorescence (excitation wavelength 530/20 nm, emission wavelength 590/20 nm) using a fluorescent plate reader.
38. Maiti M., and Kumar G.S. Med. Res. Rev. 27 (2007) 649
39. Effect on BzATP-mediated IL-1β release: THP-1 cells were differentiated by treatment for 3 h with 25 ng/ml LPS and 10 ng/ml IFNγ. The differentiated cells were incubated for 30 min with 1 μM of each 5,6-dihydrodibenzo[a,g]quinolizinium derivative, followed by stimulation with 1 mM BzATP for 30 min. Supernatants were collected by centrifugation at 1000 rpm for 5 min and assayed for the presence of mature human IL-1β using an ELISA kit.